Moreover, targeting of Vascular Endothelial Growth Factor (VEGF) has produced good results in early clinical trials, thus suggesting the critical role of this process in the development and maintenance of ovarian carcinomas [9], [10]. This evidence concerns the gene VEGFA and ovarian carcinoma.